In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 3, 2011, Pages 195-202

  Sonesson, Anders ^a   Buur Rasmussen, Birgitte ^a  

^a Ferring Pharmaceuticals AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1' HYDROXYBUFURALOL; 4' HYDROXYDICLOFENAC; 5' HYDROXYOMEPRAZOLE; 6ALPHA HYDROXYPACLITAXEL; 6BETA HYDROXYTESTOSTERONE; 8 HYDROXYEFAVIRENZ; BUFURALOL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEGARELIX; DICLOFENAC; DRUG METABOLITE; EFAVIRENZ; FURAFYLLINE; OMEPRAZOLE; ORPHENADRINE; PACLITAXEL; PARACETAMOL; PHENACETIN; PHENOBARBITAL; RIFAMPICIN; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BIOTRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; MALE; PRIORITY JOURNAL;

CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INDUCTION; GONADOTROPIN-RELEASING HORMONE; HEPATOCYTES; HUMANS; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OLIGOPEPTIDES; SUBSTRATE SPECIFICITY;

EID: 80051587825     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00709.x     Document Type: Article

References (42)

1. Mabic S, Castagnoli K, Castagnoli N Jr. Oxidative metabolic bioactivation of xenobiotics. In: Woolf TF (ed.). Handbook of Drug Metabolism. Marcel Dekker Inc., New York, NY, 1999;49-79.
2. Clarke SE, Jones BC. Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In: Rodrigues AD (ed.). Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences, Vol. 116. Marcel Dekker Inc., New York, NY, 2002;55-88.
3. Silva JM, Nicoll-Griffith DA. In vitro models for studying induction of cytochrome P450 enzymes. In: Rodrigues AD (ed.). Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences, Vol. 116. Marcel Dekker Inc., New York, NY, 2002;189-216.
4. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004;32:647-60.
5. US Food and Drug Administration. Guidance for industry drug interaction studies - study design, data analysis, and implications for dosing and labeling. (last accessed on September 2006).
6. Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P et al. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001;44:453-67.
7. Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs 2009;69:1967-76.
8. Sonesson A, Buur Rasmussen B. In vitro and in vivo metabolism of degarelix, a new anti prostate cancer peptide drug. Drug Metab Rev 2008;40:223-4.
9. Pommerville PJ, de Boer JG. GnRH antagonists in the treatment of advanced prostate cancer. Can J Urol 2010;17:5063-70.
10. Hewitt NJ, Lechón MJG, Houston JB, Hallifax D, Brown HS, Maurel P et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007;39:159-234.
11. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 1998;87:1502-7.
12. Clarke SE, Ayrton AD, Chenery RJ. Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 1994;24:517-26.
13. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300.
14. Guo Z, Raeissi S, White RB, Stevens JC. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos 1997;25:390-3.
15. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-6.
16. Walsky RL, Obach RS, Gaman EA, Gleeson J-PR, Proctor WR. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 2005;33:413-8.
17. TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci 1993;52:29-34.
18. Kanazawa H, Okado A, Higaki M, Yokota H, Mashige F, Nakahara K. Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype. J Pharm Biomed Anal 2003;30:1817-24.
19. Franklin MR, Constance JE. Comparative 1-substituted imidazole inhibition of cytochrome P450 isozyme-selective activities in human and mouse hepatic microsomes. Drug Metab Rev 2007;39:309-22.
20. Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich P et al. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 1994;46:568-77.
21. Wang RW, Newton DJ, Scheri TD, Lu AYH. Human cytochrome P450 3A4-catalyzed testosterone 6β-hydroxylation and erythromycin N-demethylation. Drug Metab Dispos 1997;25:502-7.
22. Goda R, Nagai D, Akiyama Y, Nishikawa K, Ikemoto I, Aizawa Y et al. Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Drug Metab Dispos 2006;34:828-35.
23. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990;3:566-73.
24. Brady JF, Xiao F, Wang M-H, Li Y, Ning SM, Gapac JM et al. Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes, and hepatotoxicity in rats. Toxicol Appl Pharmacol 1991;108:366-73.
25. Emery MG, Jubert C, Thummel KE, Kharasch ED. Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J Pharmacol Exp Ther 1999;291:213-9.
26. Quistorff B, Dich J, Grunnet N. Preparation of isolated rat liver hepatocytes. In: Pollar JW, Walker JM (eds). Methods in Molecular Biology, Vol. 5, Animal Cell Culture. Humana Press, Clifton, NJ, 1989;151-60.
27. LeCluyse EL, Bullok P, Parkinson A, Hochman JH. Cultured rat hepatocytes. In: Borchardt RT, Wilson G, Smith P (eds). Pharmaceutical Biotechnology, Vol. 8, Model Systems for Biopharmaceutical Assessment of Drug Absorption and Metabolism. Plenum Press, New York, 1996;121-59.
28. Mudra DR, Parkinson A. Preparation of hepatocytes. In: Maines MD (ed.). Current Protocols in Toxicology, Vol. 2. John Wiley and Sons, Inc., New York, 2001;unit 14.2.
29. Madan A, Dehaan R, Mudra D, Carroll K, LeCluyse E, Parkinson A. Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. Drug Metab Dipos 1999;27:327-35.
30. Faucette SR, Hawke RL, LeCluyse EL, Shord SS, Yan B, Laethem RM et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000;28:1222-30.
31. Li X-Q, Björkman A, Andersson TB, Ridderström M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002;300:399-407.
32. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 1994;33:1743-52.
33. Timbrell J. Principles of Biochemical Toxicology, 3rd edn. Taylor & Francis, London, 2000;65-112.
34. Korzekwa KR. In vitro enzyme kinetics applied to drug-metabolizing enzymes. In: Rodrigues AD (ed.). Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences, Vol. 116. Marcel Dekker Inc., New York, NY, 2002;33-54.
35. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998;37:4137-47.
36. Hutzler JM, Kolwankar D, Hummel MA, Tracy TS. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos 2002;30:1194-200.
37. Hutzler JM, Frye RF, Korzekwa KR, Branch RA, Huang S-M, Tracey TS. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Eur J Pharm Sci 2001;14:47-52.
38. Ramadoss P, Marcus C, Perdew GH. Role of the aryl hydrocarbon receptor in drug metabolism. Expert Opin Drug Metab Toxicol 2005;1:9-21.
39. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by pregnane X receptor. J Pharmacol Exp Therap 2004;308:495-501.
40. Sahi J, Shord SS, Lindley C, Ferguson S, LeCluyse EL. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J Biochem Mol Toxicol 2009;23:43-58.
41. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003;31:421-31.
42. Quattrochi LC, Guzelian PS. CYP3A regulation: from pharmacology to nuclear receptors. Drug Metab Dispos 2001;29:615-22.